
Panelists challenge the belief that testosterone fuels prostate cancer, explain PSA on therapy and TRAVERSE BPH data, and weigh Schedule III status.
Uppsala, Sweden-Q-Med has received FDA approval to market Deflux, a treatmentfor vesicoureteral reflux grades II-IV in children.





